340B Drug Pricing Program
Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals.
Press Release
Statement on Senate HELP Committee Hearing on Drug Pricing
Tom Nickels
Executive Vice President
American Hospital Association
The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January.
The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate.
“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for…
Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for individuals and the entire health care system.
One program that has a 25-year track record of improving access to medications and health care services for people in vulnerable…
The Health Resources and Services Administration today delayed, in accordance with a recent White House memorandum, the effective date of its final rule on drug ceiling prices and civil monetary penalties for
The administration yesterday withdrew the Health Resources and Services Administration’s pending omnibus guidance for the 340B Drug Pricing Program. “We are pleased that the Administration chose not to finalize the Health Resources and Services Administration’s guidance, which, if enacted…
The Health Resources and Services Administration today released a final rule on drug ceiling prices and civil monetary penalties for manufacturers in the 340B Drug Pricing Program.
The Health Resources and Services Administration’s proposed rule that would establish an administrative dispute resolution process for the 340B Drug Pricing Program “is an important first step for 340B hospitals and clinics that have been overcharged for drugs purchased through the program,” but…